BackGlenmark Pharmaceuticals Limited Overview

Glenmark Pharmaceuticals Limited Receivables

Track Glenmark Pharmaceuticals Limited's receivables ($50B) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$49.63B
↑ 18.71% YoYΔ $7.82B vs prior year quarter

Peer trimmed avg / median

Loading

Glenmark Pharmaceuticals Limited Receivables History

Loading

Glenmark Pharmaceuticals Limited vs. peers: Receivables Comparison

Loading

Glenmark Pharmaceuticals Limited Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Glenmark Pharmaceuticals Limited (GLENMARK.NS) FAQ

The latest receivables for GLENMARK.NS is $50B as of March 2026. That compares with $42B in the prior-year period — up 18.7% year over year. Investors often review this figure alongside Glenmark Pharmaceuticals Limited's historical trend and sector peers before judging valuation or financial health.

Over the past year, GLENMARK.NS's receivables moved from $42B to $50B — a 18.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Glenmark Pharmaceuticals Limited's operating scale or balance-sheet position.

A receivables figure of $50B for GLENMARK.NS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting GLENMARK.NS's receivables ($50B), review year-over-year change from $42B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.